Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Hu, Yun Sheng ^a   Pan, Yong ^b   Li, Wen Hai ^a   Zhang, Yong ^a   Li, Jun ^a   Ma, Bao An ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR LOCALIZATION; ASIAN; BONE TUMOR; CANCER INVASION; CHI SQUARE DISTRIBUTION; CHINA; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; PATHOLOGY; PHENOTYPE; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; OSTEOSARCOMA; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 77953698596     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-169     Document Type: Article

References (37)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995, 75(1 Suppl):203-210. 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V, 8000997.
2. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg 2009, 17(8):515-527.
3. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, Yan YX, Russo C, Sato J, Barbier N, Miser J, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994, 12(5):925-930.
4. Massague J. TGFbeta in Cancer. Cell 2008, 134(2):215-230. 10.1016/j.cell.2008.07.001, 18662538.
5. Neil JR, Galliher AJ, Schiemann WP. TGF-beta in cancer and other diseases. Future Oncol 2006, 2(2):185-189. 10.2217/14796694.2.2.185, 16563087.
6. Podar K, Raje N, Anderson KC. Inhibition of the TGF-beta signaling pathway in tumor cells. Recent Results Cancer Res 2007, 172:77-97. full_text, 17607937.
7. Mioh H, Chen JK. Differential inhibitory effects of TGF-beta on EGF-, PDGF-, and HBGF-1-stimulated MG63 human osteosarcoma cell growth: possible involvement of growth factor interactions at the receptor and postreceptor levels. J Cell Physiol 1989, 139(3):509-516. 10.1002/jcp.1041390309, 2472412.
8. Seitz PK, Zhu BT, Cooper CW. Effect of transforming growth factor beta on parathyroid hormone receptor binding and cAMP formation in rat osteosarcoma cells. J Bone Miner Res 1992, 7(5):541-546. 10.1002/jbmr.5650070510, 1319667.
9. Pontbriant CM, Chen JK, Orlando JA. TGF-beta inhibits the platelet-derived growth factor-induced formation of inositol trisphosphate in MG-63 human osteosarcoma cells. J Cell Physiol 1990, 145(3):488-495. 10.1002/jcp.1041450314, 1703169.
10. Derynck R, Feng XH. TGF-beta receptor signaling. Biochim Biophys Acta 1997, 1333(2):F105-150.
11. Roberts AB. TGF-beta signaling from receptors to the nucleus. Microbes Infect 1999, 1(15):1265-1273. 10.1016/S1286-4579(99)00258-0, 10611754.
12. Chen T, Jackson CR, Link A, Markey MP, Colligan BM, Douglass LE, Pemberton JO, Deddens JA, Graff JR, Carter JH. Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer. Clin Cancer Res 2006, 12(2):392-397. 10.1158/1078-0432.CCR-05-1518, 16428477.
13. Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol 2007, 8(1):61-73. 10.1007/s11864-007-0021-5, 2670199, 17634833.
14. Song B, Margolin S, Skoglund J, Zhou X, Rantala J, Picelli S, Werelius B, Lindblom A. TGFBR1*6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer. Br J Cancer 2007, 97(8):1175-1179. 10.1038/sj.bjc.6603961, 2360454, 17848956.
15. Chen T, Jackson C, Costello B, Singer N, Colligan B, Douglass L, Pemberton J, Deddens J, Graff JR, Carter JH. An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder. Int J Cancer 2004, 112(3):420-425. 10.1002/ijc.20419, 15382067.
16. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003, 21(17):3236-3243. 10.1200/JCO.2003.11.524, 12947057.
17. Castillejo A, Rothman N, Murta-Nascimento C, Malats N, Garcia-Closas M, Gomez-Martinez A, Lloreta J, Tardon A, Serra C, Garcia-Closas R, et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 2009, 124(3):608-613. 10.1002/ijc.24013, 19004027.
18. Castillejo A, Mata-Balaguer T, Montenegro P, Ochoa E, Lazaro R, Martinez-Canto A, Castillejo MI, Guarinos C, Barbera VM, Guillen-Ponce C, et al. The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study. BMC Cancer 2009, 9:193. 10.1186/1471-2407-9-193, 2708189, 19538729.
19. Cox DG, Penney K, Guo Q, Hankinson SE, Hunter DJ. TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study. BMC Cancer 2007, 7:175. 10.1186/1471-2407-7-175, 2082040, 17848193.
20. Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C, Ostrer H, Chen Y, Ahsan H, Offit K, et al. No major association between TGFBR1*6A and prostate cancer. BMC Genet 2004, 5:28. 10.1186/1471-2156-5-28, 521683, 15385056.
21. You W, Liu Z, Zhao J, Zheng M, Zheng SY, Liu X, Zhang HT. No association between TGFBR1*6A and lung cancer. J Thorac Oncol 2007, 2(7):657-659. 10.1097/JTO.0b013e318070ccd7, 17607123.
22. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer 1988, 57(6):594-600. 2246450, 3044431.
23. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993, 4(5):493-540.
24. Miyajima A, Asano T, Seta K, Asano T, Kakoi N, Hayakawa M. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology 2003, 61(5):1072-1077. 10.1016/S0090-4295(02)02553-0, 12736050.
25. Zeng Q, Phukan S, Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang GY, Huang CC, Valle L, et al. Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res 2009, 69(2):678-686. 10.1158/0008-5472.CAN-08-3980, 2668823, 19147584.
26. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ, Moses HL. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005, 65(6):2296-2302. 10.1158/0008-5472.CAN-04-3272, 15781643.
27. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, Wright CV, Moses HL. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006, 20(22):3147-3160. 10.1101/gad.1475506, 1635149, 17114585.
28. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang CF, Siddiqui Y, Nord J, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006, 20(10):1331-1342. 10.1101/gad.1413306, 1472907, 16702406.
29. Munoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006, 66(20):9837-9844. 10.1158/0008-5472.CAN-06-0890, 17047044.
30. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Expression of transforming growth factor-beta (TGF-beta) receptors, TGF-beta 1 and TGF-beta 2 production and autocrine growth control in osteosarcoma cells. Int J Cancer 1994, 58(3):440-445. 10.1002/ijc.2910580323, 8050825.
31. Noda M, Rodan GA. Type beta transforming growth factor (TGF beta) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. J Cell Physiol 1987, 133(3):426-437. 10.1002/jcp.1041330303, 3480288.
32. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, et al. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999, 59(22):5678-5682.
33. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007, 2:6. 10.1186/1750-1172-2-6, 1794406, 17244349.
34. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996, 86(4):531-542. 10.1016/S0092-8674(00)80127-0, 8752208.
35. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002, 109(12):1551-1559. 151012, 12070302.
36. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009, 19(1):89-102. 10.1038/cr.2008.316, 19050696.
37. Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res 2008, 68(5):1319-1328. 10.1158/0008-5472.CAN-07-5424, 2673101, 18316594.